typhoid vaccine, live oral (Vivotif) Report issue

Vaccine Approved FDA
AACT

Active Ingredient History

NOW
  • Now
Ty21a is a live attenuated bacterial vaccine that protects against typhoid. First licensed in Europe in 1983 and in the United States in 1989, it is an orally administered, live-attenuated Ty2 strain of S. Typhi in which multiple genes, including the genes responsible for the production of Vi, have been deleted so as to render it harmless but nevertheless immunogenic. It is one of the three typhoid vaccines currently recommended by the World Health Organization.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

ty21a, vivotif berna | typhoid vaccine, live oral | vivotif

Organizations (8)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

Typhoid-Paratyphoid Vaccines (approved 1989)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Cholera Vaccines (Phase 4)

Colitis, Ulcerative (Phase 2)

Healthy Volunteers (Phase 4)

Hepatitis A (Phase 4)

Inflammation (Early Phase 1)

Influenza, Human (Phase 4)

Intestinal Neoplasms (Early Phase 1)

Risk Reduction Behavior (Phase 4)

Typhoid Fever (Phase 4)

Typhoid-Paratyphoid Vaccines (Phase 4)

Vaccines (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue